Exai Bio Novel RNA-based Liquid Biopsy Platform May Detect Colorectal Cancer Early

September 12, 2022
Exai Bio, a next-generation liquid biopsy company, and researchers led by Professor Hani Goodarzi at UCSF are presenting data from a new study in a poster entitled "Serum-based colorectal cancer detection using orphan noncoding RNAs" at the 2022 European Society of Medical Oncology (ESMO) meeting.

Erasca Presents Promising Preliminary Phase 1 Monotherapy Data

September 09, 2022
Erasca, Inc., a clinical-stage precision oncology company founded by University of California chemical biologist Kevan Shokat, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors...

Arsenal Biosciences Closes $220 Million Series B Financing

September 06, 2022
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors founded on Medtech developed by Kole Roybal and Alex Marson at the University of California, San Francisco, today announced the close of a $220 million...

Talking Tech Transfer With Anthony Francis

September 02, 2022
With a career that already stretches decades, Francis has a lot of wisdom to share, such as the need to understand that universities and investors trade in different currencies: innovation and money. MORE

Trial Library Emerges Out of Stealth with $5 Million in Seed Funding

August 22, 2022
Fresh Capital Used to Build on Trial Library's Mission to Improve Health Equity by Expanding Access to Cancer Precision Medicine Spearheaded by Dr. Hala Borno, Leading UCSF oncologist and Health Equity Researcher. Press Release

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion

August 08, 2022
The proposed acquisition brings leading sickle cell disease expertise to Pfizer with potential combined worldwide peak sales of more than $3 billion to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics...

Mission Bio Launches Early Access Program That Can Detect Cancer in Individual Cells

August 01, 2022
 Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced the initial availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells, launching a new era for the understanding of...

Sonoma Bio Clears FDA Hurdle

July 25, 2022
 Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S.

Neurona Therapeutics Dosed Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy

June 30, 2022
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epi

Erasca Announces Trial to Evaluate ERAS-007

June 23, 2022
“We look forward to ERAS-007 being evaluated in this trial, based in part on ERAS-007's ability in preclinical studies to robustly shut down oncogenic signaling,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. MORE